MARX Biotech（7731）株式概要株式会社マルクスバイオテックは、男性用健康食品と化粧品のオンライン販売を行っている。 詳細7731 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績2/6財務の健全性2/6配当金1/6報酬今年は黒字化を達成 リスク分析負債は営業キャッシュフローで十分にカバーされていない 高いレベルの非現金収入 TW市場と比較した過去 3 か月間の株価の変動意味のある時価総額がありません ( NT$3B )すべてのリスクチェックを見る7731 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueNT$Current PriceNT$5.4950.8% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-97m636m2016201920222025202620282031Revenue NT$635.9mEarnings NT$42.9mAdvancedSet Fair ValueView all narrativesMARX Biotech Co., Ltd. 競合他社MedFirst Healthcare ServicesSymbol: TPEX:4175Market cap: NT$2.2bNorbel BabySymbol: TPEX:6844Market cap: NT$2.5bGreat Tree PharmacySymbol: TPEX:6469Market cap: NT$10.5bSimple Mart RetailSymbol: TWSE:2945Market cap: NT$2.8b価格と性能株価の高値、安値、推移の概要MARX Biotech過去の株価現在の株価NT$5.4952週高値NT$10.6052週安値NT$3.90ベータ0.741ヶ月の変化-19.74%3ヶ月変化-8.65%1年変化-8.19%3年間の変化n/a5年間の変化n/aIPOからの変化-37.61%最新ニュースお知らせ • Mar 27MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026. Location: 13 floor no,659, pan s. rd., jhonghe district, new taipei city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$3.01b market cap, or US$95.8m).New Risk • Jan 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$2.21b market cap, or US$69.8m).New Risk • Jul 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$326m free cash flow). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (NT$2.56b market cap, or US$86.9m).Reported Earnings • Apr 13Full year 2024 earnings released: NT$0.19 loss per share (vs NT$0.03 loss in FY 2023)Full year 2024 results: NT$0.19 loss per share (further deteriorated from NT$0.03 loss in FY 2023). Revenue: NT$618.2m (up 113% from FY 2023). Net loss: NT$96.8m (loss widened NT$83.9m from FY 2023).New Risk • Apr 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.05b (US$92.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$3.05b market cap, or US$92.1m).最新情報をもっと見るRecent updatesお知らせ • Mar 27MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026. Location: 13 floor no,659, pan s. rd., jhonghe district, new taipei city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$3.01b market cap, or US$95.8m).New Risk • Jan 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$2.21b market cap, or US$69.8m).New Risk • Jul 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$326m free cash flow). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (NT$2.56b market cap, or US$86.9m).Reported Earnings • Apr 13Full year 2024 earnings released: NT$0.19 loss per share (vs NT$0.03 loss in FY 2023)Full year 2024 results: NT$0.19 loss per share (further deteriorated from NT$0.03 loss in FY 2023). Revenue: NT$618.2m (up 113% from FY 2023). Net loss: NT$96.8m (loss widened NT$83.9m from FY 2023).New Risk • Apr 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.05b (US$92.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$3.05b market cap, or US$92.1m).お知らせ • Mar 28MARX Biotech Co., Ltd., Annual General Meeting, Jun 16, 2025MARX Biotech Co., Ltd., Annual General Meeting, Jun 16, 2025, at 09:30 Taipei Standard Time. Location: 13 floor no,659, pan nan rd., jhonghe district, new taipei city TaiwanNew Risk • Mar 03New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$74m free cash flow). Share price has been highly volatile over the past 3 months (8.0% average weekly change). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).New Risk • Jan 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$74m free cash flow). Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change).New Risk • Jan 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.28b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$74m free cash flow). Minor Risk Market cap is less than US$100m (NT$3.28b market cap, or US$99.6m).お知らせ • Mar 16MARX Biotech Co., Ltd., Annual General Meeting, May 30, 2024MARX Biotech Co., Ltd., Annual General Meeting, May 30, 2024.株主還元7731TW Consumer RetailingTW 市場7D-11.0%-4.6%6.6%1Y-8.2%-18.5%102.0%株主還元を見る業界別リターン: 7731過去 1 年間で-18.5 % の収益を上げたTW Consumer Retailing業界を上回りました。リターン対市場: 7731は、過去 1 年間で102 % のリターンを上げたTW市場を下回りました。価格変動Is 7731's price volatile compared to industry and market?7731 volatility7731 Average Weekly Movement11.6%Consumer Retailing Industry Average Movement3.0%Market Average Movement6.2%10% most volatile stocks in TW Market12.3%10% least volatile stocks in TW Market2.5%安定した株価: 7731の株価は、 TW市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 7731の weekly volatility ( 12% ) は過去 1 年間安定していますが、依然としてTWの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2015n/aYanchao Yangmarxbiotech.comMARX Biotech Co., Ltd.は、メンズヘルスとコスメシューティカル製品のオンライン小売に従事している。同社は2016年に設立され、台湾の新北市に拠点を置く。もっと見るMARX Biotech Co., Ltd. 基礎のまとめMARX Biotech の収益と売上を時価総額と比較するとどうか。7731 基礎統計学時価総額NT$2.98b収益（TTM）NT$42.92m売上高(TTM)NT$635.85m66.8xPER（株価収益率4.5xP/Sレシオ7731 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計7731 損益計算書（TTM）収益NT$635.85m売上原価NT$241.26m売上総利益NT$394.59mその他の費用NT$351.67m収益NT$42.92m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）0.082グロス・マージン62.06%純利益率6.75%有利子負債／自己資本比率85.3%7731 の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.0%現在の配当利回り70%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 13:47終値2026/05/26 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MARX Biotech Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 27MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026. Location: 13 floor no,659, pan s. rd., jhonghe district, new taipei city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$3.01b market cap, or US$95.8m).
New Risk • Jan 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$2.21b market cap, or US$69.8m).
New Risk • Jul 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$326m free cash flow). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (NT$2.56b market cap, or US$86.9m).
Reported Earnings • Apr 13Full year 2024 earnings released: NT$0.19 loss per share (vs NT$0.03 loss in FY 2023)Full year 2024 results: NT$0.19 loss per share (further deteriorated from NT$0.03 loss in FY 2023). Revenue: NT$618.2m (up 113% from FY 2023). Net loss: NT$96.8m (loss widened NT$83.9m from FY 2023).
New Risk • Apr 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.05b (US$92.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$3.05b market cap, or US$92.1m).
お知らせ • Mar 27MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026. Location: 13 floor no,659, pan s. rd., jhonghe district, new taipei city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$3.01b market cap, or US$95.8m).
New Risk • Jan 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$2.21b market cap, or US$69.8m).
New Risk • Jul 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$326m free cash flow). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (NT$2.56b market cap, or US$86.9m).
Reported Earnings • Apr 13Full year 2024 earnings released: NT$0.19 loss per share (vs NT$0.03 loss in FY 2023)Full year 2024 results: NT$0.19 loss per share (further deteriorated from NT$0.03 loss in FY 2023). Revenue: NT$618.2m (up 113% from FY 2023). Net loss: NT$96.8m (loss widened NT$83.9m from FY 2023).
New Risk • Apr 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.05b (US$92.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$3.05b market cap, or US$92.1m).
お知らせ • Mar 28MARX Biotech Co., Ltd., Annual General Meeting, Jun 16, 2025MARX Biotech Co., Ltd., Annual General Meeting, Jun 16, 2025, at 09:30 Taipei Standard Time. Location: 13 floor no,659, pan nan rd., jhonghe district, new taipei city Taiwan
New Risk • Mar 03New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$74m free cash flow). Share price has been highly volatile over the past 3 months (8.0% average weekly change). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
New Risk • Jan 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$74m free cash flow). Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change).
New Risk • Jan 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.28b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$74m free cash flow). Minor Risk Market cap is less than US$100m (NT$3.28b market cap, or US$99.6m).
お知らせ • Mar 16MARX Biotech Co., Ltd., Annual General Meeting, May 30, 2024MARX Biotech Co., Ltd., Annual General Meeting, May 30, 2024.
